Harrow is an ophthalmic-focused pharmaceutical company. Co. engages in the development, production, sale and distribution of prescription medications. Co. owns and operates ImprimisRx, the ophthalmology-focused pharmaceutical-compounding business, and its branded drugs are marketed under its Harrow name. In addition, Co. also has non-controlling equity positions in Surface Ophthalmics, Inc., which is focused on development and commercialization of therapeutics for ocular surface diseases; and Melt Pharmaceuticals, Inc., which is focused on the development and commercialization of proprietary non-intravenous, sedation and anesthesia therapeutics for human medical procedures. We show 23 historical shares outstanding datapoints in our coverage of HROW's shares outstanding history.
Understanding the changing numbers of HROW shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like HROW versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching HROW by allowing them to research HROW shares outstanding history
as well as any other stock in our coverage universe. |
Free HROW Email Alerts:
Video: Shares Outstanding Importance
